Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies : a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid))
Sanmartín, O. (Fundació Institut Valencià d'Oncologia)
Gúrpide, A. (Clínica Universidad de Navarra)
España, A. (Clínica Universidad de Navarra)
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau)
Suh Oh, H.J. (Complejo Hospitalario Universitario de Pontevedra)
Aragón, I. (Complejo Hospitalario Universitario de Huelva)
Segura, S. (Hospital del Mar (Barcelona, Catalunya))
Beato, C. (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Botella, R. (Instituto de Investigación Sanitaria La Fe)
Universitat Autònoma de Barcelona

Fecha:	2019
Resumen:	Progress in the understanding of many tumors has enabled the development of new therapies, such as those targeted at specific molecules involved in cell growth (targeted therapies) or intended to modulate the immune system (immunotherapy). However, along with the clinical benefit provided by these new treatments, new adverse effects have also appeared. Dermatological toxicities such as papulopustular eruptions, xerosis, and pruritus are common with EGFR inhibitors. Other adverse effects have also been described with PDGFR, BCR-ABL, and MAPK tyrosine kinase inhibitors, antiangiogenic drugs, and inhibitors at immune checkpoints such as CTLA-4 and PD-1/PD-L1. Onset of these adverse effects often causes dose reductions and/or delays in administering the prescribed therapy, which can affect patient survival and quality of life. It is, therefore, important to prevent the occurrence of these adverse effects, or to treat unavoidable ones as soon as possible. This requires cooperation between medical oncologists and dermatologists. This article reviews the various dermatological toxicities associated with targeted therapies and immunotherapies, along with their diagnosis and therapeutic management.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Anti-EGFR ; Antiangiogenic drugs ; Dermatological toxicity ; Immune checkpoint inhibitors ; MTOR inhibitors ; Targeted therapies
Publicado en:	Clinical & Translational Oncology, Vol. 21 Núm. 5 (january 2019) , p. 556-571, ISSN 1699-3055

DOI: 10.1007/s12094-018-1953-x
PMID: 30284232

16 p, 2.1 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados